Advances in the study of biological agents in the treatment of Crohn’s disease

Update:Sep. 18, 2021Total Views:1712Total Downloads:594 DownloadMobile

Author: Han-Han ZHENG 1, 2 Xue-Liang JIANG 3

Affiliation: 1. Department of Gastroenterology, Shandong Police General Hospital, Jinan 250000, China 2. Department of Gastroenterology, Shandong Nanshan Hospital, Jinan 250000, China 3. Department of Gastroenterology, the Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250001, China

Keywords: Crohn’s disease Biological agents Treatment

DOI:10.12173/j.issn.1004-5511.202011054

Reference:Zheng HH, Jiang XL. Advances in the study of biological agents in the treatment of Crohn's disease. DOI: 10.12173/j.issn.1004-5511.202011054.[Article in Chinese]

  • Abstract
  • Full-text
  • Figures and Tables
  • References
Abstract

Crohn’s disease (CD) is a chronic, non-specific intestinal inflammatory disease. A large number of clinical trials have shown that biological agents are effective in inducing remission in patients with CD, and mainte-nance treatment can achieve long-term remission. At present, biological agents are now being widely used in the treatment of CD and have become the main treatment. These include the anti-tumor necrosis factor (TNF)-α monoclo-nal antibodies, anti-integrin antibody, IL-12/23 monoclonal antibody and a Janus kinase (JAK) inhibitor. In this article, we review the progress and selection of biologics in the treatment of CD.

Full-text
Please download the PDF version to read the full text: download
References

1.吴大鹏, 郑萍. 英夫利西治疗克罗恩病11例疗效观察[J]. 国际消化病杂志, 2010, 30(5): 314-315, 318. DOI: 10.3969/j.issn.1673-534X.2010.05.019. [Wu DP, Zheng P. Efficacy infliximab of treatment in 11 patients with Crohn's disease[J]. International Journal of Digestive Diseases, 2010, 30(5): 314-315, 318.]

2.Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease[J]. Gastroenterology, 2015, 148(7): 1320-1329.e3. DOI: 10.1053/j.gastro.2015.02.031.

3.Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial[J]. Gastroenterology, 2006, 130(2): 323-333. DOI: 10.1053/j. gastro.2005.11.030.

4.Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial[J]. Ann Intern Med, 2007, 146(12): 829-838. DOI: 10.7326/0003-4819-146-12-200706190-00159.

5.Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's dis-ease: results of the CLASSIC II trial[J]. Gut, 2007, 56(9): 1232-1239. DOI: 10.1136/gut.2006.106781.

6.Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial[J]. Gastroenterology, 2007, 132(1): 52-65. DOI: 10.1053/j.gastro.2006.11.041.

7.Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents[J]. Inflamm Bowel Dis, 2007, 13(11): 1323-1332. DOI: 10.1002/ibd. 20225.

8.Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease[J]. Gastroenterology, 2005, 129(3): 807-818. DOI: 10.1053/j.gastro.2005.06.064.

9.Hébuterne X, Lémann M, Bouhnik Y, et al. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol[J]. Gut, 2013, 62(2): 201-208. DOI: 10.1136/gutjnl-2012-302262.

10.中华医学会消化病学分会炎症性肠病学组. 抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)[J]. 协和医学杂志, 2017, 8(4): 239-243. DOI: 10.3969/j.issn.1674-9081.2017.05.009. [Chinese Society of Gastroen-terology, IBD Working Group. Expert consensus on anti-tumor necrosis factor alpha monoclonal an-tibody in the treatment of inflammatory bowel disease (2017)[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4): 239-243.]

11.林果为,王吉耀,葛均波. 实用内科学(第15版)[M]. 北京: 人民卫生出版社, 2017. [Lin GW, Wang JY, Ge JB. Practical Internal Medicine (15th edition)[M]. Beijing: People's Medical Publishing House, 2017.]

12.Lu ZY, Chen WC, Li YH, et al. TNF-α enhances vascular cell adhesion molecule-1 expression in human bone marrow mesenchymal stem cells via the NF-κB, ERK and JNK signaling pathways[J]. Mol Med Rep, 2016, 14(1): 643-648. DOI: 10.3892/mmr.2016.5314.

13.Zundler S, Becker E, Weidinger C, et al. Anti-adhesion therapies in inflammatory bowel dis-ease-molecular and clinical aspects[J]. Front Immunol, 2017, 8: 891. DOI: 10.3389/fimmu.2017.00891.

14.Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial[J]. Gastroenterology, 2007, 132(5): 1672-1683. DOI: 10.1053/j.gastro.2007.03.024.

15.Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis[J]. Am J Gastroenterol, 2011, 106(4): 644-659. DOI: 10.1038/ajg.2011.73.

16.Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2013, 369(8): 711-721. DOI: 10.1056/NEJMoa1215739.

17.Singh S, Garg SK, Pardi DS, et al. Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis[J]. Mayo Clin Proc, 2014, 89(12): 1621-1635. DOI: 10.1016/j.mayocp.2014.08.019.

18.Barré A, Colombel JF, Ungaro R. Review article: predictors of response to vedolizumab and usteki-numab in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2018, 47(7): 896-905. DOI: 10.1111/apt.14550.

19.Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natali-zumab therapy for Crohn's disease[J]. N Engl J Med, 2005, 353(4): 362-368. DOI: 10.1056/NEJMoa051586.

20.Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis[J]. N Engl J Med, 2005, 353(4): 369-374. DOI: 10.1056/NEJMoa051782.

21.Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab[J]. N Engl J Med, 2005, 353(4): 375-381. DOI: 10.1056/NEJMoa051847.

22.Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease[J]. Gut, 2017, 66(5): 839-851. DOI: 10.1136/gutjnl-2015- 311079.

23.Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases[J]. J Pharmacol Exp Ther, 2009, 330(3): 864-875. DOI: 10.1124/jpet.109.153973.

24.Moschen AR, Tilg H, Raine T. IL-12,IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(3): 185-196. DOI: 10.1038 /s41575-018-0084-8.

25.Greving CA, Towne J. A role for IL-12 in IBD after all?[J]. Immunity, 2019, 51(2): 209-211. DOI: 10.1016/j.immuni.2019.07.008.

26.Sun H, Sun C, Xiao W, et al. Tissue-resident lymphocytes: from adaptive to innate immunity[J]. Cell Mol Immunol, 2019, 16(3): 205-215. DOI: 10.1038/s41423-018-0192-y.

27.Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn's disease[J]. N Engl J Med, 2016, 375(20): 1946-1960. DOI: 10.1056/NEJMoa1602773.

28.Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn's disease[J]. J Crohns Colitis, 2020, 14(1): 23-32. DOI: 10.1093/ecco-jcc/jjz110.

29.姚嘉茵, 宋孝美, 余乔, 等. 乌司奴单克隆抗体治疗难治性克罗恩病的短期疗效分析:一项多中心回顾性观察性研究[J].中华炎性肠病杂志, 2021, 5(2): 151-155. DOI: 10.3760/cma.j.cn101480-20210326-00025. [Yao JY, Song XM, Yu Q, et al. Analysis of the short-term efficacy of ustekinumab for intractable Crohn's disease: a multicenter retrospective observational study[J]. Chinese Journal of Inflammatory Bowel Diseases, 2021, 5(2): 151-155.]

30.Sandborn WJ, Rutgeerts P, Gasink C, et al. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy[J]. Aliment Pharmacol Ther, 2018, 48(1): 65-77. DOI: 10.1111/apt.14794.

31.Apostolos K, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and au-toimmune disease[J]. Curr Opin Pharmacol, 2012, 12(4): 464-470.DOI: 10.1016/j.coph.2012.06.008.

32.Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease[J]. Clin Gastroenterol Hepatol, 2014, 12(9): 1485-1493.e2. DOI: 10.1016/j.cgh.2014.01.029.

33.Chudy-Onwugaje KO, Christian KE, Farraye FA, et al. A state-of-the-art review of new and emerging therapies for the treatment of IBD[J]. Inflamm Bowel Dis, 2019, 25(5): 820-830. DOI: 10.1093/ibd/izy327.

34.Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials[J]. Gut, 2017, 66(6): 1049-1059. DOI: 10.1136/ gutjnl-2016-312735.

35.Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease[J]. Gastroenterology, 2021, 160(7): 2496-2508.DOI: 10.1053/j.gastro.2021.04.022.

36.Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcera-tive colitis controlled trials[J]. Aliment Pharmacol Ther, 2017, 45(10): 1291-1302. DOI: 10.1111/apt.14030.

37.Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease[J]. Gastroenterology, 2005, 128(4): 862-869. DOI: 10.1053/j. gas-tro.2005.01.048.

38.Colombel JF, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease[J]. Gut, 2009, 58(7): 940-948. DOI: 10.1136/gut.2008.159251.

39.Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with out-come of interventions after loss of response to infliximab or adalimumab[J]. Clin Gastroenterol Hepa-tol, 2015, 13(3): 522-530. DOI: 10.1016/j.cgh.2014.07.029. 

40.Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor[J]. Aliment Pharmacol Ther, 2020, 51(10): 948-957. DOI: 10.1111/apt.15706.

41.杨红, 金梦, 钱家鸣. 选择不同生物制剂治疗炎症性肠病:如何平衡风险和获益[J]. 中华炎性肠病杂, 2020, 4(1): 25-29. DOI: 10.3760/cma.j.issn.2096-367X.2020.01.007. [Yang H, Jin M, Qian JM. Choice of different bi-ological agents in inflammatory bowel disease: how to balance risks and benefits[J]. Chinese Journal of Inflammatory Bowel Diseases, 2020, 4(1): 25-29.]

42.Puchner A, Gröchenig HP, Sautner J, et al. Immunosuppressives and biologics during pregnancy and lactation: a consensus report issued by the Austrian Societies of Gastroenterology and Hepatology and Rheumatology and Rehabilitation[J]. Wien Klin Wochenschr, 2019, 131: 29-44. DOI: 10.1007/s00508-019-1448-y. 

43.Aliyev ER, Hay JW, Hwang C. Cost-effectiveness comparison of ustekinumab, infliximab, or adalimumab for the treatment of moderate-severe Crohn's disease in biologic-naïve patients[J]. Pharmacotherapy, 2019, 39(2): 118-128. DOI: 10.1002/phar.2208. 

44.Holko P, Kawalec P, Pilc A. Cost-effectiveness analysis of Crohn's disease treatment with vedolizumab and ustekinumab after failure of tumor necrosis factor-α antagonist[J]. Pharmacoeconomics, 2018, 36(7): 853-865. DOI: 10.1007/s40273-018-0653-2.

45.Reinglas J, Gonczi L, Kurt Z, et al. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases[J]. World J Gastroenterol, 2018, 24(32): 3567-3582. DOI: 10.3748/wjg.v24.i32.3567.

Hot Papers